Regulation of RAGE for Attenuating Progression of Diabetic Vascular Complications by Win, Myat Thu Thu et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 894605, 8 pages
doi:10.1155/2012/894605
Review Article
Regulation of RAGE for Attenuating Progression of Diabetic
Vascular Complications
MyatThu Thu Win,YasuhikoYamamoto, SeiichiMunesue,HidehitoSaito, Dong Han,
SoMotoyoshi, TarekKamal,TakuroOhara,TakuoWatanabe,andHiroshiYamamoto
Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science,
Kanazawa 920-8640, Japan
Correspondence should be addressed to Yasuhiko Yamamoto, yasuyama@med.kanazawa-u.ac.jp
Received 23 July 2011; Revised 8 August 2011; Accepted 16 August 2011
Academic Editor: Daisuke Koya
Copyright © 2012 Myat Thu Thu Win et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Diabetic angiopathy including micro- and macroangiopathy is concerned with high rate of morbidity and mortality in patients
with long-standing diabetes. Receptor for advanced glycation end products (RAGE) and its ligands have been considered as
important pathogenic triggers for the progression of the vascular injuries in diabetes. The deleterious link between RAGE and
diabetic angiopathy has been demonstrated in animal studies. Preventive and therapeutic strategies focusing on RAGE and its
ligand axis may be of great importance in relieving diabetic vascular complications and reducing the burden of disease.
1.Introduction
Diabetes is a life-threatening disease attributing to its devas-
tating complications such as cardiovascular disease, stroke,
and microvascular diseases. The population worldwide with
diabetes is estimated to be 285 million adults in 2010, and
it will reach 439 million adults by 2030 with overall total
predicted 54% increase [1]. The very recent study reports
the number of people with diabetes already came to 347
million in 2008 [2]. In proportion to the rapid increase of
diabetic population, diabetic nephropathy is now a major
cause of end-stage renal disease and diabetic retinopathy
is a leading cause of blindness [3]. Extensive intracellular
and extracellular formation of advanced glycation end-
products (AGE) is considered to be a causative factor in sus-
tained hyperglycemia-induced vascular injuries in diabetes.
Receptor-dependent and receptor independent mechanisms
are known to work in the AGE-induced cellular dysfunction
and tissue damage. The receptor for AGE (RAGE) is origi-
nally found as an AGE-binding receptor and now recognized
as a proinﬂammatory molecular devise mediating danger
signals to the body. In this paper, our current understanding
about RAGE and its multiligand system will be reviewed




Maillard ﬁrst described the formation of brown-colored
substances resulted from nonenzymatic reaction between
reducing sugar and proteins [4]. There is a chemical linkage
between the carbonyl groups and the amino group to
form Schiﬀ bases and then Amadori compounds, followed
by irreversible dehydration, condensation, and crosslinking,
resulting in heterogeneous derivatives termed AGE [5].
Similar reactions have been found to occur with nonglucose
materials containing an aldehyde group by enzymatic and
non-enzymatic pathways. Metabolites from glycolysis path-
way such as dicarbonyls of methylglyoxal (MG), glyoxal,
and 3-deoxyglucosone (3DG) are known to interact with
protein residues to rapidly form AGE [6]. Reactive dicar-
bonyls can be also generated from ketones, lipids, and other
metabolic pathways [7]. Increased production of the reactive
dicarbonyls or reducing detoxiﬁcation by the glyoxalase
system or endogenous scavengers leads to a state of carbonyl
stress, which is increasingly considered to be the major
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Figure 1: RAGE and its ligands play a role in the development of diabetic vascular complications. Soluble RAGE (sRAGE) and endogenous
soluble RAGE (esRAGE) may work as decoy receptors against ligand-RAGE interactions. AGE: advanced glycation end product; AOPP:
advanced oxidation protein product; HMGB1: high-mobility group box protein 1.
Glyoxal is also produced by auto-oxidation of glucose
and 3-deoxyglucosone (3DG) generated by hydrolysis from
Amadori rearrangement products [9]. Glycolaldehyde pro-
duction by myeloperoxidase from activated macrophages
and neutrophils plays a pathogenic role in generating
AGE and damaging tissues at sites of inﬂammation [10].
Formation of AGE is accelerated under hyperglycemia in
diabetes. Some AGE have intrinsic ﬂuorescence which can
be used as a surrogate marker for the presence of AGE
modiﬁcations. AGE are chemically heterogeneous groups of
compounds with only 25 AGE structures fully characterized.
Nε-carboxymethyl-lysine (CML) is the simplest and best
characterized AGE and the main epitope for recognition
by most commercially available antibodies used for the
detection and quantiﬁcation of AGE. Exogenously oﬀered
AGE are absorbed in the gastrointestinal tract (∼10%),
and approximately two-thirds remained in contact with
tissues for >72hr, whereas the rest is rapidly excreted by
the kidneys [11–13]. Reducing basal oxidative stress by
AGE restriction in mice, without energy or nutrient change,
alleviates inﬂammation, prevents vascular complications,
and extends normal life span [14, 15].
3. RAGE
The best characterized AGE receptor is RAGE. RAGE
belongs to the immunoglobulin (Ig) superfamily of cell-
surface molecules and is composed of an extracellular region
containing one V-type and two C-type Ig domains [16]. This
portion of the receptor joins a hydrophobic transmembrane-
spanning domain and then a highly charged, short cyto-
plasmic domain that is essential for post-RAGE signaling
[16, 17]. RAGE is a member of a family of pattern-
recognition receptors that function at the interface of innate
and adaptive immunity. Its endogenous and exogenous
binding partners include AGE, high-mobility group box 1
(HMGB1), calcium-binding S100 protein group, β2-integrin
Mac/CD11b, amyloid β-peptide, β-sheet ﬁbrils, advanced
oxidation protein products (AOPPs), complement C3a,
lipopolysaccharides (LPS), and phosphatidylserine on the
surface of apoptotic cells [18–24]( Figure 1). Ligand engage-
ment of RAGE activates the nuclear factor-κB( N F - κB) and
other signaling pathways through stimulation of ERK (extra-
cellular signal-regulated kinase)1/2, p38 MAPK (mitogen-
activated-protein-kinase)-JNK (c-Jun N-terminal kinases),
JAK (Janus-kinase)-STAT (signal transducer and activator
of transcription), and Rac-Cdc42, many of which are the
results as well as the cause of reactive oxygen species (ROS)
[25]. Subsequently, expression of inﬂammatory cytokines is
increased, which leads to an inﬂammatory response with
associated cellular migration and proliferation. Recently,
mammalian homologue of Drosophila gene Diaphanous 1
(mDia1) has been identiﬁed as a direct binding partner
of an intracellular domain of RAGE and as a part of the
machinery of RAGE intracellular signaling [26]. The mDia1
exists widely from yeast to the mammal and is known to
link with cell division, polarity formation, and movements
by actin polymerization [26]. Ligation of RAGE causes a
positive feed-forward loop, in which inﬂammatory stimuli
activate NF-κB, which induces RAGE expression, followed
again by NF-κBa c t i v a t i o n[ 27].
Self-downregulation system of RAGE is also reported: as
an example, the binding of HMGB1 to RAGE induces an
intracellular signal transduction as well as RAGE sheddingExperimental Diabetes Research 3
by a disintegrin and metalloproteinase domain-containing
protein 10 (ADAM10) [28]. The cleavage of the membrane-
bound full-length and signal transducing RAGE yields sol-
uble RAGE (sRAGE), which could work as a decoy receptor
against ligand-RAGE interactions. In the strict sense of the
word, sRAGE is a heterogeneous population of total sRAGE
proteins, including soluble splice variants of RAGE and the
proteinase-cleaved forms of membrane-bound RAGE and
of the soluble splice variants [29]. Endogenous secretory
RAGE (esRAGE) is one of the major splice variants of
RAGE detected in blood, cell surface and cytoplasm of
vascular endothelial cells, pancreatic β-cells, monocytes,
macrophages, and so on [30, 31]. The sRAGE is thought to
act locally and systemically as a decoy receptor. Reinforcing
the ectodomain shedding will decrease a total amount and
expression of signal-transducing RAGE and will reciprocally
increase an amount of decoy receptor sRAGE; this can
control ligand-RAGE signaling and subsequent cellular and
tissue derangement [32]. It is also reported that sRAGE
mediates inﬂammation by directly binding to monocytes
underlessligandconditionsthoughthemechanismofaction
is unknown [33]. Recent clinical studies have focused on
the signiﬁcance of circulating sRAGE or esRAGE in diabetic
vascular complications. Findings in both type 1 and type 2
diabetic patients are quite confusing and both inverse and
positivecorrelationshavebeenreportedindiabeticretinopa-
thy, nephropathy, and incident cardiovascular disease events
and mortality outcomes [29, 34–39]. First, production of
sRAGE and esRAGE is inducible. Second, the presence of
renal insuﬃciency can strongly and positively inﬂuence
c i r c u l a t i n gs R A G Eo re s R A G El e v e l[ 29]. Third, medications
may alter sRAGE or esRAGE level. All phenomena may
explain controversial ﬁndings of sRAGE or esRAGE in
diabetes.
4.OtherReceptors
Many other AGE receptors and soluble binding proteins
interacting with AGE may play an important role in the AGE
homeostasis: scavenger receptors class A (MSR-A), class B
(MSR-B) (CD36 and LOX1), AGE-R1 (OST48 oligosaccha-
ryltransferase), AGE-R2 (80K-H protein kinase C substrate),
AGE-R3 (galectin-3), and toll-like receptor (TLR) 4 [40–44].
There are also other molecules like lysozyme and lactoferrin-
like polypeptide involving in cellular uptake and degradation
of AGE [45]. AGE-R1 is a type I transmembrane receptor
found on the plasma membrane and in the endoplasmic
reticulum [40]. The cell surface membrane-associated AGE-
R1 blocks responses to AGE by blocking the induction of
ROS-mediated activation of MAPK/Ras and inﬂammatory
molecules, induced in part via RAGE [46]. Torreggiani et
al. showed that the overexpression of AGE-R1 in mice is
associatedwithdecreasedbasallevelsofcirculatingandtissue
AGE and oxidative stress and signiﬁcant protection against
wire injury-induced femoral artery intimal hyperplasia and
inﬂammation [47]. AGE-R3 (galectin-3) is also reported to
work as an AGE receptor to protect AGE-induced tissue
injury via AGE removal or degradation [41, 42].
5.DiabeticNephropathy
ToevaluatewhetherRAGEandligandsystemmayparticipate
in the development of diabetic nephropathy, we created
transgenic mice that overexpress human RAGE proteins in
endothelial cells and crossbred them with another transgenic
mouse line that develops insulin-dependent diabetes early
after birth [48]. The resultant double transgenic mice
showed signiﬁcant increases in kidney weight, albuminuria,
glomerulosclerosis, and serum creatinine compared with
the diabetic control [48–50]. Indices diagnostic of diabetic
retinopathy were also most prominent in double transgenic
mice. Our group also generated RAGE knockout (KO) mice
and reported the marked improvement of nephromegaly,
albuminuria, glomerulosclerosis, and increase of serum cre-
atinine level in diabetic RAGE-KO mice [51]. The kidneys of
streptozotocin (STZ)-injected RAGE-KO mice were reported
to be protected from early mesangial matrix expansion and
thickening of the glomerular basement membrane (GBM)
seen in wild-type diabetic mice [52]. Moreover, RAGE
deletion was also beneﬁcial to diabetic nephropathy seen in
OVE26 type 1 diabetic mice with progressive glomeruloscle-
rosis and decline of renal function [53].R¨ usteretal.reported
an interaction between the renin-angiotensin system and the
AGE-RAGE axis in podocytes [54]. Since intraglomerular
angiotensin II levels are increased in diabetic nephropathy,
this interaction may have pathophysiological consequences
for podocyte injury and inﬂammation associated with the
development of diabetic nephropathy [54]. Pharmacological
blockade of RAGE, using sRAGE in db/db diabetic mice,
protected against glomerulosclerosis and other classical
lesions of early diabetic nephropathy [52]. It admits no
doubt that RAGE plays a major role in diabetic nephropathy
(Table 1).
6.DiabeticRetinopathy
Diabetes retinopathy is classiﬁed into nonproliferative stage
(NPDR) and proliferative stage (PDR). NPDR is character-
ized by capillary microangiopathy, microaneurysms, base-
ment membrane thickening, and loss of pericytes [55]. An
association between accumulation of CML and expression
of vascular endothelial growth factor (VEGF) has also been
foundineyeswithnon-PDRandPDR[56].VEGFappearsto
be the most important growth factor in diabetic retinopathy.
It is also well documented that oxidative stress is linked to
AGE formation, and involved in retinal vascular dysfunction
[57]. RAGE expression has been predominantly localized
to glia in the inner retina, and the expression appeared to
be upregulated in diabetic conditions [58]. Other ligands
for RAGE including S100 proteins and HMGB1 are evident
in the vitreous and preretinal membranes of eyes with
PDR [59]. Kaji et al. demonstrated blood-retinal barrier
breakdown and increased leukostasis in endothelial RAGE-
overexpressing mice and their amelioration by the treatment
of sRAGE [60]. RAGE activation by ligand in M¨ uller glia
results in ERK1/2 activation and subsequent production4 Experimental Diabetes Research
Table 1: RAGE and its ligand axis in diabetic angiopathy using
RAGE gene-manipulated animal models.
Animal models Phenotypes References
Diabetic nephropathy
RAGE transgenic mice Nephropathy ↑ [48, 50]
(Type 1 diabetes)
+ AGE inhibitor Nephropathy ↓
RAGE knockout mice Nephropathy ↓ [51, 93]
(Type 1 diabetes)
+ LMWH treatment Nephropathy ↓
RAGE knockout mice Nephropathy ↓ [53]
(Type 1 diabetes, OVE26)
db/db mice + sRAGE Nephropathy ↓ [52]
RAGE knockout mice Nephropathy ↓
(STZ-diabetes)
Diabetic retinopathy
RAGE transgenic mice Retinopathy ↑ [60]
(STZ-diabetes)
+ sRAGE treatment Retinopathy ↓
RAGE transgenic mice Retinopathy ↑ [80]
(Type 1 diabetes)
Diabetic neuropathy
RAGE knockout mice Neuropathy ↓ [63]
(STZ diabetes)
+ sRAGE treatment Neuropathy ↓
RAGE knockout mice Neuropathy ↓ [64]
(STZ diabetes)
of inﬂammatory cytokines such as VEGF and MCP-1,
implicating the critical role of RAGE in neovascularization
and recruitment of immune cells such as microglia into the
deep retinal layers during diabetic retinopathy to induce
inﬂammation [58].
7.DiabeticNeuropathy
In diabetic neuropathy, both autonomic and peripheral
nerves are aﬀected. Endothelial injury may impair the
blood ﬂow which leads to hypoxia and oxidative stress in
peripheral nerves [61]. Wada and Yagihashi demonstrated
the expression of RAGE in the perineural and endoneurial
endothelial cells and schwann cells of peripheral nerve in
rat by in situ hybridization [62]. Models of experimental
diabetic neuropathy provided sound evidence that deletion
of the RAGE gene protected animals from the detrimental
eﬀects of diabetes, while overexpression of RAGE promotes
diabetic neuropathy [63–66]. Moreover, the loss of thermal
pain perception observed in mice with diabetes could be
prevented by treatment with sRAGE. In agreement with
these observations, NF-κB activation and the loss of pain
perception were largely blunted in RAGE-KO mice [63].
8. Atherosclerosis
AGE stimulate ROS generation in vascular wall cells
and subsequently induce redox-sensitive atherosclerosis-
related molecular expressionsuch as MCP-1, matrix metallo-
proteinase-9(MMP-9),andplasminogenactivatorinhibitor-
1 (PAI-1), all of which could contribute to the formation and
destabilization of coronary atherosclerotic plaques [67, 68].
AGE induce increased vascular permeability, procoagulant
activity, migration of macrophages and T cells into the
intima, and impairment of endothelium-dependent relax-
ation [69]. AGE inhibition attenuated accelerated atheroma
associated with diabetes [70]. STZ-induced diabetic ApoE-
KO mice clearly showed that RAGE activation has a central
role in the formation and progression of atherosclerotic
lesions and that the absence of RAGE was associated with
a signiﬁcant attenuation of the atherosclerotic plaque [71].
Competitive inhibition of RAGE by exogenously adminis-
trated sRAGE resulted in a decrease in mean atherosclerotic
lesion area and number of complex lesions [72, 73]. In
addition, RAGE inactivation also inhibited atherosclero-
sis through blocking the RAGE-mediated inﬂammatory
reactions and oxidative stress in nondiabetic models with
atherosclerosis of ApoE-KO and low-density lipoprotein
(LDL) receptor KO mice [74].
In atherosclerosis, increased level of LDL and presence of
small dense LDL are strong and independent risk factors and
both are features of dyslipidemia [75]. The speciﬁc protein
of apolipoprotein B (ApoB) on LDL is glycated in diabetes
[76], and this leads to rapid scavenger uptake of the LDL
[77], which gives rise to foam cell formation in atherogenesis
[69]. The oxidation and glycation of LDL are partially
interdependent and indisputably coexist, and both prevent
LDL receptor-mediated uptake and promote macrophage
scavenger receptor-mediated LDL uptake. Small dense LDL
is more preferentially glycated in vivo and more susceptible
to glycation in vitro than buoyant LDL [78]. Glycated-high
density lipoprotein (HDL) has also been linked to decreased
ability to prevent monocyte adhesion to aortic endothelial
cells [79], while lipoprotein A glycation has been shown
to increase PAI-1 production and decrease t-PA generation
[80, 81]. Glycated LDL and HDL may also play an important
role in atherogenesis.
9. Conclusion
Diabetic angiopathy is still a burden disease worldwide
even though new pharmaceutical interventions are available.
Applications of inhibitors for AGE and RAGE may be
prospective therapeutic approaches for prophylaxis and
treatment of diabetic angiopathy. Benfotiamine is a synthetic
S-acyl derivative of thiamine and has antioxidant and anti-
AGE formation properties [82]. Thiazolium compounds
ALT-711 (algebrium), C36, TRC4186, and TRC4149 and
their prototype N-phenacylthiazolium bromide (PTB) are
known as AGE breakers, which break preaccumulated AGE
or existing AGE cross-links [83–86].
TTP488 is an antagonist against RAGE [87]. Low-
molecular-weight heparin (LMWH) can bind RAGE and actExperimental Diabetes Research 5
as an antagonist to RAGE [51]. LMWH treatment of mice
showed preventive and therapeutic eﬀects on albuminuria
and increased glomerular cell number, mesangial expan-
sion, and advanced glomerulosclerosis in a dose-dependent
manner [51]. Thiazolidinediones, calcium channel block-
ers, angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin II receptor blockers (ARBs), and statins are
reported to suppress RAGE expression [88–90].Treatmentof
statins and ACEI stimulated circulating sRAGE production
in human studies [91, 92]. It is interesting in the future to
develop new devices and remedies of controlling the RAGE
ectodomain shedding. New therapeutic strategies are desired
to prevent diabetic vascular complications and to improve
both quantity and quality of life in patients with diabetes.
References
[1] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates
of the prevalence of diabetes for 2010 and 2030,” Diabetes
Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010.
[2] G. Danaei, M. M. Finucane, Y. Lu et al., “National, regional,
andglobaltrendsinfastingplasmaglucoseanddiabetespreva-
lence since 1980: systematic analysis of health examination
surveys and epidemiological studies with 370 country-years
and 2.7 million participants,” The Lancet, vol. 2, no. 378,
pp. 31–40, 2011.
[3] Diabetes statistics, Data from the 2011 national diabetes fact
sheet,2011,http://www.diabetes.org/diabetes-basics/diabetes-
statistics.
[4] L. C. Maillard, “Action des acides amin´ es sur les sucres:
formation des m´ elano¨ ıdines par voie m´ ethodique,” Compte-
rendu de l’Acad´ emie des sciences, pp. 66–68, 1912.
[5] H.Yamamoto,T.Watanabe,Y.Yamamotoetal.,“RAGEindia-
betic nephropathy,” Current Molecular Medicine, vol. 7, no. 8,
pp. 752–757, 2007.
[6] N. Rabbani and P. J. Thornalley, “Dicarbonyls linked to dam-
age in the powerhouse: glycation of mitochondrial proteins
and oxidative stress,” Biochemical Society Transactions, vol. 36,
no. 5, pp. 1045–1050, 2008.
[7] V. Riddle and F. W. Lorenz, “Nonenzymic, polyvalent anion-
catalyzed formation of methylglyoxal as an explanation of
its presence in physiological systems,” Journal of Biological
Chemistry, vol. 243, no. 10, pp. 2718–2724, 1968.
[8] P. J. Thornalley, “The glyoxalase system: new developments
towards functional characterization of a metabolic pathway
fundamental to biological life,” Biochemical Journal, vol. 269,
no. 1, pp. 1–11, 1990.
[9] R. Nagai, C. M. Hayashi, L. Xia, M. Takeya, and S. Hori-
uchi, “Identiﬁcation in human atherosclerotic lesions of GA-
pyridine, a novel structure derived from glycolaldehyde-
modiﬁed proteins,” Journal of Biological Chemistry, vol. 277,
no. 50, pp. 48905–48912, 2002.
[10] R. Nagai, K. Matsumoto, X. Ling, H. Suzuki, T. Araki, and
S. Horiuchi, “Glycolaldehyde, a reactive intermediate for
advanced glycation end products, plays an important role in
the generation of an active ligand for the macrophage scav-
enger receptor,” Diabetes, vol. 49, no. 10, pp. 1714–1723, 2000.
[11] T. Koschinsky, C. J. He, T. Mitsuhashi et al., “Orally absorbed
reactive glycation products (glycotoxins): an environmental
risk factor in diabetic nephropathy,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 94, no. 12, pp. 6474–6479, 1997.
[12] H. Vlassara, W. Cai, J. Crandall et al., “Inﬂammatory markers
are induced by dietary glycotoxins: a pathway for accelerated
atherosclerosis in diabetes,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 99,
no. 24, pp. 15596–15601, 2002.
[13] W. Cai, Q. D. Gao, L. Zhu, M. Peppa, C. He, and H. Vlassara,
“Oxidative stress-inducing carbonyl compounds from
common foods: novel mediators of cellular dysfunction,”
Molecular Medicine, vol. 8, no. 7, pp. 337–346, 2002.
[14] M. Peppa, C. He, M. Hattori, R. McEvoy, F. Zheng, and H.
Vlassara, “Fetal or neonatal low-glycotoxin environment pre-
vents autoimmune diabetes in NOD mice,” Diabetes, vol. 52,
no. 6, pp. 1441–1448, 2003.
[15] H.VlassaraandG.E.Striker,“AGErestrictionindiabetesmel-
litus: a paradigm shift,” Nature Reviews Endocrinology, vol. 7,
no. 9, pp. 526–539, 2011.
[16] M. Neeper, A. M. Schmidt, J. Brett et al., “Cloning and expres-
sion of a cell surface receptor for advanced glycosylation end
products of proteins,” Journal of Biological Chemistry, vol. 267,
no. 21, pp. 14998–15004, 1992.
[17] H. J. Huttunen, C. Fages, and H. Rauvala, “Receptor for
advanced glycation end products (RAGE)-mediated neurite
outgrowth and activation of NF-κB require the cytoplasmic
domain of the receptor but diﬀerent downstream signaling
pathways,” Journal of Biological Chemistry, vol. 274, no. 28,
pp. 19919–19924, 1999.
[18] T. Kislinger, C. Fu, B. Huber et al., “N(ε)-(carboxymeth-
yl)lysine adducts of proteins are ligands for receptor for
advanced glycation end products that activate cell signaling
pathways and modulate gene expression,” Journal of Biological
Chemistry, vol. 274, no. 44, pp. 31740–31749, 1999.
[19] M. A. Hofmann, S. Drury, C. Fu et al., “RAGE mediates a
novel proinﬂammatory axis: a central cell surface receptor
for S100/calgranulin polypeptides,” Cell,v o l .9 7 ,n o .7 ,p p .
889–901, 1999.
[20] O. Hori, J. Brett, T. Slattery et al., “The receptor for advanced
glycation end products (RAGE) is a cellular binding site
for amphoterin. Mediation of neurite outgrowth and co-
expression of RAGE and amphoterin in the developing ner-
vous system,” Journal of Biological Chemistry, vol. 270, no. 43,
pp. 25752–25761, 1995.
[21] S. D. Yan, X. Chen, J. Fu et al., “RAGE and amyloid-β peptide
neurotoxicity in Alzheimer’s disease,” Nature, vol. 382, no.
6593, pp. 685–691, 1996.
[22] T. Chavakis, A. Bierhaus, N. Al-Fakhri et al., “The pattern
recognition receptor (RAGE) is a counterreceptor for leuko-
cyte integrins: a novel pathway for inﬂammatory cell recruit-
ment,” Journal of Experimental Medicine, vol. 198, no. 10,
pp. 1507–1515, 2003.
[23] Y. Yamamoto, A. Harashima, H. Saito et al., “Septic shock is
associated with receptor for advanced glycation end products
ligation of LPS,” Journal of Immunology, vol. 186, no. 5, pp.
3248–3257, 2011.
[24] M. He, H. Kubo, K. Morimoto et al., “Receptor for advanced
glycation endproductsbindstophosphatidylserineandassists
in the clearance of apoptotic cells,” EMBO Reports, vol. 12, no.
4, pp. 358–364, 2011.
[ 2 5 ]D .P .B a r l o v i c ,A .S o r o - P a a v o n e n ,a n dK .A .M .J a n d e l e i t -
Dahm, “RAGE biology, atherosclerosis and diabetes,” Clinical
Science, vol. 121, no. 2, pp. 43–55, 2011.
[26] B. I. Hudson, A. Z. Kalea, M. D. M. Arriero et al., “Interaction
of the RAGE cytoplasmic domain with diaphanous-1 is
required for ligand-stimulated cellular migration through6 Experimental Diabetes Research
activation of Rac1 and Cdc42,” Journal of Biological Chemistry,
vol. 283, no. 49, pp. 34457–34468, 2008.
[27] A. Bierhaus, S. Schiekofer, M. Schwaninger et al., “Diabetes-
associated sustained activation of the transcription factor
nuclear factor-κB,” Diabetes, vol. 50, no. 12, pp. 2792–2808,
2001.
[28] A. Raucci, S. Cugusi, A. Antonelli et al., “A soluble form of
the receptor for advanced glycation endproducts (RAGE) is
produced by proteolytic cleavage of the membrane-bound
form by the sheddase a disintegrin and metalloprotease 10
(ADAM10),” FASEB Journal, vol. 22, no. 10, pp. 3716–3727,
2008.
[29] Y. Yamamoto, J. Miura, S. Sakurai et al., “Assaying soluble
forms of receptor for advanced glycation end products,” Arte-
riosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6,
pp. e33–e34, 2007.
[30] H. Yonekura, Y. Yamamoto, S. Sakurai et al., “Expression and
function of novel splice variants of RAGE in human vascular
endothelial cells and pericytes,” Biochemical Journal, vol. 370,
no. 3, pp. 1097–1109, 2003.
[31] C. Cheng, K. Tsuneyama, R. Kominami et al., “Expression
proﬁling of endogenous secretory receptor for advanced
glycation end products in human organs,” Modern Pathology,
vol. 18, no. 10, pp. 1385–1396, 2005.
[32] R. Nagai, T. Mori, Y. Yamamoto, Y. Kaji, and Y. Yonei,
“Signiﬁcance of advanced glycation end products (AGEs) in
aging-related disease,” Anti-Aging Medicine, vol. 7, no. 10, pp.
112–119, 2010.
[33] Y. Wang, H. Wang, M. G. Piper et al., “sRAGE induces
human monocyte survival and diﬀerentiation,” Journal of
Immunology, vol. 185, no. 3, pp. 1822–1835, 2010.
[34] S. Sakurai, Y. Yamamoto, H. Tamei et al., “Development of
an ELISA for esRAGE and its application to type 1 diabetic
patients,”DiabetesResearchandClinicalPractice,vol.73,no.2,
pp. 158–165, 2006.
[35] H. Koyama, T. Shoji, S. Fukumoto et al., “Low circulating
endogenous secretory receptor for AGEs predicts cardiovas-
cular mortality in patients with end-stage renal disease,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no.
1, pp. 147–153, 2007.
[36] N. Katakami, M. Matsuhisa, H. Kaneto et al., “Serum
endogenous secretory RAGE level is an independent risk
factor for the progression of carotid atherosclerosis in type 1
diabetes,” Atherosclerosis, vol. 204, no. 1, pp. 288–292, 2009.
[37] X. H. Tam, S. W. Shiu, L. Leng, R. Bucala, D. J. Betteridge,
and K. C. Tan, “Enhanced expression of receptor for advanced
glycation end-products is associated with low circulating
soluble isoforms of the receptor in type 2 diabetes,” Clinical
Science, vol. 120, no. 2, pp. 81–89, 2011.
[ 3 8 ] M .C .T h o m a s ,J .S¨ oderlund, M. Lehto et al., “Soluble receptor
for AGE (RAGE) is a novel independent predictor of all-cause
and cardiovascular mortality in type 1 diabetes,” Diabetologia,
vol. 54, no. 10, pp. 2669–2677, 2011.
[39] H. M. Colhoun, D. J. Betteridge, and P. Durrington, “Total
soluble and endogenous secretory receptor for advanced
glycation endproducts as predictive biomarkers of coronary
heart disease risk in patients with type 2 diabetes: an
analysis from the CARDS Trial,” Diabetes,v o l .6 0 ,n o .9 ,p p .
2379–2385, 2011.
[40] Z. Yang, Z. Makita, Y. Horii et al., “Two novel rat liver
membrane proteins that bind advanced glycosylation
endproducts: relationship to macrophage receptor for
glucose-modiﬁed proteins,” Journal of Experimental Medicine,
vol. 174, no. 3, pp. 515–524, 1991.
[41] H.Vlassara,Y.M.Li,Y.Imanietal.,“Identiﬁcationofgalectin-
3 as a high-aﬃnity binding protein for advanced glycation
end products (AGE): a new member of the AGE-receptor
complex,” MolecularMedicine,vol.1,no.6,pp.634–646,1995.
[42] W. Zhu, H. Sano, R. Nagai, K. Fukuhara, A. Miyazaki,
and S. Horiuchi, “The role of galectin-3 in endocytosis
of advanced glycation end products and modiﬁed low
density lipoproteins,” Biochemical and Biophysical Research
Communications, vol. 280, no. 4, pp. 1183–1188, 2001.
[43] H. Suzuki, Y. Kurihara, M. Takeya et al., “A role for
macrophage scavenger receptors in atherosclerosis and
susceptibility to infection,” Nature, vol. 386, no. 6633, pp.
292–296, 1997.
[44] C. P. Hodgkinson, R. C. Laxton, K. Patel, and S. Ye, “Advanced
glycation end-product of low density lipoprotein activates
the toll-like 4 receptor pathway implications for diabetic
atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 28, no. 12, pp. 2275–2281, 2008.
[45] T. Mitsuhashi, Y. M. Li, S. Fishbane, and H. Vlassara,
“Depletion of reactive advanced glycation end products from
diabetic uremic sera using a lysozyme-linked matrix,” Journal
of Clinical Investigation, vol. 100, no. 4, pp. 847–854, 1997.
[46] C. Lu, J. C. He, W. Cai, H. I. Liu, L. Zhu, and H. Vlassara,
“Advanced glycation endproduct (AGE) receptor 1 is a
negative regulator of the inﬂammatory response to AGE
in mesangial cells,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 101, no. 32, pp.
11767–11772, 2004.
[47] M. Torreggiani, H. Liu, J. Wu et al., “Advanced glycation
end product receptor-1 transgenic mice are resistant to
inﬂammation, oxidative stress, and post-injury intimal
hyperplasia,” American Journal of Pathology, vol. 175, no. 4,
pp. 1722–1732, 2009.
[48] Y. Yamamoto, I. Kato, T. Doi et al., “Development and
prevention of advanced diabetic nephropathy in RAGE-
overexpressingmice,”JournalofClinicalInvestigation,vol.108,
no. 2, pp. 261–268, 2001.
[49] Y. Yamamoto, S. Yamagishi, H. Yonekura et al., “Roles of the
AGE-RAGE system in vascular injury in diabetes,” Annals of
the New York Academy of Sciences, vol. 902, pp. 163–172, 2000.
[50] R. Inagi, Y. Yamamoto, M. Nangaku et al., “A severe diabetic
nephropathy model with early development of nodule-like
lesions induced by megsin overexpression in RAGE/iNOS
transgenic mice,” Diabetes, vol. 55, no. 2, pp. 356–366, 2006.
[51] K. M. Myint, Y. Yamamoto, T. Doi et al., “RAGE control of
diabetic nephropathy in a mouse model: eﬀects of RAGE
gene disruption and administration of low-molecular weight
heparin,” Diabetes, vol. 55, no. 9, pp. 2510–2522, 2006.
[52] T. M. Wendt, N. Tanji, J. Guo et al., “RAGE drives the
development of glomerulosclerosis and implicates podocyte
activation in the pathogenesis of diabetic nephropathy,” Amer-
ican Journal of Pathology, vol. 162, no. 4, pp. 1123–1137, 2003.
[53] N. Reiniger, K. Lau, D. McCalla et al., “Deletion of the
receptor for advanced glycation end products reduces
glomerulosclerosisandpreservesrenalfunctioninthediabetic
OVE26 mouse,” Diabetes, vol. 59, no. 8, pp. 2043–2054, 2010.
[54] C. R¨ uster, T. Bondeva, S. Franke, N. Tanaka, H. Yamamoto,
and G. Wolf, “Angiotensin II upregulates RAGE expression
on podocytes: role of AT2 receptors,” American Journal of
Nephrology, vol. 29, no. 6, pp. 538–550, 2009.Experimental Diabetes Research 7
[55] H. P. Hammes, “Pericytes and the pathogenesis of diabetic
retinopathy,” Hormone and Metabolic Research, vol. 37, no. 1,
pp. S39–S43, 2005.
[56] T. Murata, R. Nagai, T. Ishibashi, H. Inomata, K. Ikeda,
and S. Horiuchi, “The relationship between accumulation
of advanced glycation end products and expression of
vascular endothelial growth factor in human diabetic retinas,”
Diabetologia, vol. 40, no. 7, pp. 764–769, 1997.
[ 5 7 ]T .S o u l i s ,V .T h a l l a s ,S .Y o u s s e fe ta l . ,“ A d v a n c e dg l y c a t i o n
end products and their receptors co-localise in rat organs
susceptible to diabetic microvascular injury,” Diabetologia,
vol. 40, no. 6, pp. 619–628, 1997.
[58] H. Zong, M. Ward, A. Madden et al., “Hyperglycaemia-
inducedpro-inﬂammatoryresponsesbyretinalM¨ ullergliaare
regulated by the receptor for advanced glycation end-products
(RAGE),” Diabetologia, vol. 53, no. 12, pp. 2656–2666, 2010.
[59] S. I. Pachydaki, S. R. Tari, S. E. Lee et al., “Upregulation
of RAGE and its ligands in proliferative retinal disease,”
Experimental Eye Research, vol. 82, no. 5, pp. 807–815, 2006.
[60] Y. Kaji, T. Usui, S. Ishida et al., “Inhibition of diabetic
leukostasis and blood-retinal barrier breakdown with a
soluble form of a receptor for advanced glycation end
products,” Investigative Ophthalmology and Visual Science, vol.
48, no. 2, pp. 858–865, 2007.
[61] N. E. Cameron, S. E. Eaton, M. A. Cotter, and S. Tesfaye,
“Vascular factors and metabolic interactions in the
pathogenesis of diabetic neuropathy,” Diabetologia, vol. 44,
no. 11, pp. 1973–1988, 2001.
[62] R. Wada and S. Yagihashi, “Role of advanced glycation end
products and their receptors in development of diabetic
neuropathy,” Annals of the New York Academy of Sciences, vol.
1043, pp. 599–603, 2005.
[63] A. Bierhaus, K. M. Haslbeck, P. M. Humpert et al., “Loss
of pain perception in diabetes is dependent on a receptor
of the immunoglobulin superfamily,” Journal of Clinical
Investigation, vol. 114, no. 12, pp. 1741–1751, 2004.
[64] C. Toth, L. L. Rong, C. Yang et al., “Receptor for advanced
glycation end products (RAGE) and experimental diabetic
neuropathy,” Diabetes, vol. 57, no. 4, pp. 1002–1017, 2008.
[65] N. Yajima, Y. Yamamoto, H. Yamamoto et al., “Peripheral
neuropathy in diabetic mice overexpressing receptor for
advanced glycation end products (RAGE),” in Proceedings of
the 8th International Symposium on the Maillard reaction,n o .
SXI-7, p. 55, Charleston, SC, USA, 2004.
[66] A. M. Vincent, L. Perrone, K. A. Sullivan et al., “Receptor for
advanced glycation end products activation injures primary
sensory neurons via oxidative stress,” Endocrinology, vol. 148,
no. 2, pp. 548–558, 2007.
[67] A. M. Schmidt and D. M. Stern, “RAGE: a new target for the
prevention and treatment of the vascular and inﬂammatory
complications of diabetes,” Trends in Endocrinology and
Metabolism, vol. 11, no. 9, pp. 368–375, 2000.
[68] A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager,
“Advanced glycation end products: sparking the development
of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp.
597–605, 2006.
[69] R.Bucala,K.J.Tracey,andA.Cerami,“Advancedglycosylation
products quench nitric oxide and mediate defective
endothelium-dependent vasodilatation in experimental
diabetes,” Journal of Clinical Investigation,v o l .8 7 ,n o .2 ,p p .
432–438, 1991.
[70] J. M. Forbes, L. T. L. Yee, V. Thallas et al., “Advanced glycation
end product interventions reduce diabetes-accelerated
atherosclerosis,” Diabetes, vol. 53, no. 7, pp. 1813–1823, 2004.
[71] A. Soro-Paavonen, A. M. Watson, J. Li et al., “Receptor
for advanced glycation end products (RAGE) deﬁciency
attenuates the development of atherosclerosis in diabetes,”
Diabetes, vol. 57, no. 9, pp. 2461–2469, 2008.
[ 7 2 ]L .P a r k ,K .G .R a m a n ,K .J .L e ee ta l . ,“ S u p p r e s s i o no f
accelerated diabetic atherosclerosis by the soluble receptor for
advanced glycation end products,” Nature Medicine, vol. 4,
no. 9, pp. 1025–1031, 1998.
[73] T. Wendt, E. Harja, L. Bucciarelli et al., “RAGE modulates
vascular inﬂammation and atherosclerosis in a murine model
of type 2 diabetes,” Atherosclerosis, vol. 185, no. 1, pp. 70–77,
2006.
[74] L. Sun, T. Ishida, T. Yasuda et al., “RAGE mediates oxidized
LDL-induced pro-inﬂammatory eﬀects and atherosclerosis
in non-diabetic LDL receptor-deﬁcient mice,” Cardiovascular
Research, vol. 82, no. 2, pp. 371–381, 2009.
[75] A. C. St-Pierre, B. Cantin, G. R. Dagenais et al., “Low-density
lipoprotein subfractions and the long-term risk of ischemic
heart disease in men: 13-year follow-up data from the Qu´ ebec
Cardiovascular Study,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 25, no. 3, pp. 553–559, 2005.
[76] F. J. Tames, M. I. Mackness, S. Arrol, I. Laing, and P. N.
Durrington, “Non-enzymatic glycation of apolipoprotein B in
the sera of diabetic and non-diabetic subjects,” Atherosclerosis,
vol. 93, no. 3, pp. 237–244, 1992.
[77] B. E. Brown, I. Rashid, D. M. van Reyk, and M. J.
Davies, “Glycation of low-density lipoprotein results in
the time-dependent accumulation of cholesteryl esters and
apolipoprotein B-100 protein in primary human monocyte-
derived macrophages,” FEBS Journal, vol. 274, no. 6, pp.
1530–1541, 2007.
[78] H. Soran and P. N. Durrington, “Susceptibility of LDL and
its subfractions to glycation,” Current Opinion in Lipidology,
vol. 22, no. 4, pp. 254–261, 2011.
[79] C.C.Hedrick,S.R.Thorpe,M.X.Fuetal.,“Glycationimpairs
high-density lipoprotein function,” Diabetologia, vol. 43,
no. 3, pp. 312–320, 2000.
[80] C. Doucet, T. Huby, J. Ruiz, M. J. Chapman, and J. Thillet,
“Non-enzymatic glycation of lipoprotein(a) in vitro and in
vivo,” Atherosclerosis, vol. 118, no. 1, pp. 135–143, 1995.
[81] J. Zhang, S. Ren, and G. X. Shen, “Glycation ampliﬁes
lipoprotein(a)-induced alterations in the generation of
ﬁbrinolytic regulators from human vascular endothelial cells,”
Atherosclerosis, vol. 150, no. 2, pp. 299–308, 2000.
[82] A. Stirban, M. Negrean, B. Stratmann et al., “Benfotiamine
prevents macro- and microvascular endothelial dysfunction
and oxidative stress following a meal rich in advanced
glycation end products in individuals with type 2 diabetes,”
Diabetes Care, vol. 29, no. 9, pp. 2064–2071, 2006.
[83] S. B. Schwedler, P. Verbeke, H. Bakala et al., “N-phenacyl-
thiazolium bromide decreases renal and increases urinary
advanced glycation end products excretion without ame-
liorating diabetic nephropathy in C57BL/6 mice,” Diabetes,
Obesity and Metabolism, vol. 3, no. 4, pp. 230–239, 2001.
[84] D. Joshi, R. Gupta, A. Dubey et al., “TRC4186, a novel
AGE-breaker, improves diabetic cardiomyopathy and
nephropathy in Ob-ZSF1 model of type 2 diabetes,” Journal of
Cardiovascular Pharmacology, vol. 54, no. 1, pp. 72–81, 2009.
[85] B. H. Wolﬀenbuttel, C. M. Boulanger, F. R. Crijns et al.,
“Breakers of advanced glycation end products restore large
artery properties in experimental diabetes,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 95, no. 8, pp. 4630–4634, 1998.8 Experimental Diabetes Research
[86] G. Cheng, L. L. Wang, L. Long et al., “Beneﬁcial eﬀects of C36,
a novel breaker of advanced glycation end products cross-
links, on the cardiovascular system of diabetic rats,” British
Journal of Pharmacology, vol. 152, no. 8, pp. 1196–1206, 2007.
[ 8 7 ]Y .C h e n ,E .M .A k i r a v ,W .C h e ne ta l . ,“ R A G El i g a t i o na ﬀects
T cell activation and controls T cell diﬀerentiation,” Journal of
Immunology, vol. 181, no. 6, pp. 4272–4278, 2008.
[88] N. Marx, D. Walcher, N. Ivanova et al., “Thiazolidinediones
reduce endothelial expression of receptors for advanced
glycation end products,” Diabetes, vol. 53, no. 10, pp.
2662–2668, 2004.
[89] S. Yamagishi and M. Takeuchi, “Nifedipine inhibits gene
expression of receptor for advanced glycation end products
(RAGE) in endothelial cells by suppressing reactive oxygen
species generation,” Drugs under Experimental and Clinical
Research, vol. 30, no. 4, pp. 169–175, 2004.
[90] C. Cuccurullo, A. Iezzi, M. L. Fazia et al., “Suppression of
RAGE as a basis of simvastatin-dependent plaque stabilization
in type 2 diabetes,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 26, no. 12, pp. 2716–2723, 2006.
[91] F. Santilli, L. Bucciarelli, D. Noto et al., “Decreased plasma
soluble RAGE in patients with hypercholesterolemia: eﬀects
of statins,” Free Radical Biology and Medicine, vol. 43, no. 9,
pp. 1255–1262, 2007.
[ 9 2 ] J .M .F o r b e s ,S .R .T h o r p e ,V .T h a l l a s - B o n k ee ta l . ,
“Modulation of soluble receptor for advanced glycation
end products by angiotensin-converting enzyme-1 inhibition
in diabetic nephropathy,” Journal of the American Society of
Nephrology, vol. 16, no. 8, pp. 2363–2372, 2005.
[93] J. Li, X. Qu, J. Yao et al., “Blockade of endothelial-
mesenchymal transition by a Smad3 inhibitor delays the
early development of streptozotocin-induced diabetic
nephropathy,” Diabetes, vol. 59, no. 10, pp. 2612–2624, 2010.